Price
No data yet.
Social Signal Score
Analyst Ratings
6 analystsRevenue
$9.53M+217.71%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Robert G. Spignesi Jr.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 171
- Beta
- 1.48
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -18.00
Financials
Revenue
$9.53M+217.7%Net Income
$-11.27MEBITDA
$-9.92MFree Cash Flow
$-13.61MEPS (diluted)
$-0.23Shares Outstanding (diluted)
48.88M+54.0%Operating Expenses
$12.32MCash & Debt
$6.72MReturn of Capital
$0.00Revenue by Segment (annual)
$36.14MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $33.59M | $-47.12M | $-1.05 |
| 2024 | $28.05M | $-46.89M | $-1.08 |
| 2023 | $22.52M | $-52.47M | $-1.22 |
| 2022 | $17.13M | $-60.81M | $-1.43 |
| 2021 | $23.23M | $-73.52M | $-1.88 |
| 2020 | $16.08M | $-37.08M | $-1.17 |
| 2019 | $16.51M | $-21.17M | $-0.53 |
Valuation
RPIDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
142+104.33%Social Signal Score
Mentions (10)
- Newsbusinesswire.com·6d ago·Neutral
RPID Stock Alert: Halper Sadeh LLC is Investigating Whether Rapid Micro Biosystems, Inc. is Obtaining a Fair Price for its Shareholders NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Rapid Micro Biosystems, Inc. (NASDAQ: RPID) to Merck KGaA, Darmstadt, Germany for $0.75 per share. Halper Sadeh encourages Rapid shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at …
View source ↗ - Newszacks.com·6d ago·Neutral
Rapid Micro Biosystems, Inc. (RPID) Reports Q3 Loss, Beats Revenue Estimates Rapid Micro Biosystems, Inc. (RPID) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.26 per share a year ago.
View source ↗ - Newsglobenewswire.com·6d ago·Negative
Rapid Micro Biosystems Reports Third Quarter 2026 Financial Results LEXINGTON, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the third quarter ended September 30, 2026.
View source ↗ - Newsglobenewswire.com·6d ago·Negative
…Signs Definitive Agreement to be Acquired by Merck KGaA, Darmstadt, Germany LEXINGTON, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced it has signed a definitive agreement pursuant to which Merck KGaA, Darmstadt, Germany, has agreed to acquire, s…
View source ↗ - Newszacks.com·23d ago·Neutral
Rapid Micro Biosystems, Inc. (RPID) May Report Negative Earnings: Know the Trend Ahead of Q3 Release Rapid Micro Biosystems (RPID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newsglobenewswire.com·33d ago·Negative
…stems to Participate at the PDA Pharmaceutical Microbiology Conference 2026 LEXINGTON, Mass., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its participation as a sponsor of the PDA Pharmaceutical Microbiology Conference 2026, taking place in Washingt…
View source ↗ - Newsglobenewswire.com·79d ago·Negative
Rapid Micro Biosystems to Participate in Upcoming Investor Conferences LEXINGTON, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission-critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced plans to participate in the following upcoming investor conferences:
View source ↗ - Newszacks.com·79d ago·Negative
After Plunging 33.7% in 4 Weeks, Here's Why the Trend Might Reverse for Rapid Micro Biosystems (RPID) Rapid Micro Biosystems (RPID) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
View source ↗ - Newszacks.com·95d ago·Positive
Down 25.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Rapid Micro Biosystems (RPID) The heavy selling pressure might have exhausted for Rapid Micro Biosystems (RPID) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
View source ↗ - Newszacks.com·102d ago·Positive
Rapid Micro Biosystems (RPID) Upgraded to Buy: What Does It Mean for the Stock? Rapid Micro Biosystems (RPID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
View source ↗
Earnings
Thu, Mar 11(in 4 months)
Consensus estimate $-0.15 per share
Typical surprise -4.8% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 16$-0.22 vs $-0.21miss
- Fri, Aug 7$-0.27 vs $-0.24miss
- Wed, May 13$-0.31 vs $-0.25miss
- Thu, Mar 12$-0.28 vs $-0.23miss
- Fri, Nov 7$-0.26 vs $-0.26beat
- Tue, Aug 12$-0.27 vs $-0.26miss
Estimates and results for RPID via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RPID officers and directors.
- Bought
- $6.3m
- Sold
- $1.3m
3 trades
19 trades
- Bain Capital Life Sciences Investors, Llcbought
- Bain Capital Life Sciences Investors, Llcbought
- Bain Capital Life Sciences Investors, Llcbought
- Wilson John J. Addingtonsold
- Wirtjes Sean Msold
- Spignesi Robert G. Jr.sold
- Wilson John J. Addingtonsold
- Wirtjes Sean Msold
78 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RPID.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
